Basal Cell Carcinoma Treatment Market –By Treatment Type (Surgery [Type, Treatment Providers] Medications [Route of Administration, Distribution Channel), Cancer Type (Nodular, Superficial Spreading, Sclerosing, Pigmented) – Global Forecast 2024 – 2032

Basal Cell Carcinoma Treatment Market Size

Basal Cell Carcinoma Treatment Market size accounted for USD 7.1 billion in 2023 and is expected to exhibit growth at a CAGR of 8.6% from 2024 to 2032, driven by several factors such as increasing incidence of basal cell carcinoma, primarily due to heightened exposure to ultraviolet (UV) radiation and aging populations globally.
 

For instance, according to the American Academy of Dermatology (AAD), it is estimated that around 10 million individuals are diagnosed with BCC annually worldwide. This indicates the significant burden of this disease. Therefore, innovations in treatment modalities including the development of targeted therapies and immunotherapies have opened new avenues for patient care, thereby propelling the market growth. Additionally, advancements in diagnostic technologies have improved the early detection rates of basal cell carcinoma. Techniques such as dermatoscopy and advanced imaging systems enable dermatologists to identify BCC at earlier stages, leading to more timely and effective treatment interventions, thereby fostering the market growth.
 

Basal cell carcinomas treatment is a nonmelanocytic skin cancer, refers to removal of cancer cells completely with surgical interventions and appropriate medication treatment regimens including dermatology drugs. Surgery includes electrodessication and curettage, standard surgical excision and Mohs surgery along with chemotherapy as well as targeted therapy.
 

Basal Cell Carcinoma Treatment Market Trends

The expansion of the market is significantly bolstered by heightened disease awareness initiatives. Public health campaigns and educational programs have effectively raised consumer awareness pertaining to the importance of skin protection, regular skin checks, and early intervention. This surge in awareness has translated into a notable increase in the number of individuals seeking medical advice and treatment for BCC, thereby driving the demand for advanced diagnostic and therapeutic solutions.
 

For instance, as per the American Academy of Dermatology (AAD) report, there has been 25% increase in free skin cancer screenings from 2010 to 2020, resulting in the early identification of numerous skin cancer cases including BCC. Similarly, a survey by the American Cancer Society indicated a 30% rise in public knowledge of skin cancer risks and preventive measures. This heightened awareness has led to more frequent dermatological consultations, thereby accelerating the growth of the BCC treatment market.
 

Basal Cell Carcinoma Treatment Market Analysis

Based on treatment type, the market is segmented into surgery, medication, other treatment types. The surgery segment dominated the market with USD 3.5 billion in 2023.
 

• Surgical treatments including Mohs micrographic surgery are renowned for its high success rates. For instance, according to the Skin Cancer Foundation, the cure rate for new skin cancers treated with Mohs surgery is up to 99%. These procedures ensure complete removal of cancerous tissues with significantly reducing the chances of recurrence.
   
• Thus, surgery is preferrable and can be effectively employed for various sizes and types of BCCs, including those located in challenging areas such as the face. Such factors will augment the segmental growth in the coming years as well.
   
• Further, continuous advancements in surgical technologies enhance the safety, precision, and effectiveness of these treatments, thereby increasing their attractiveness to both patients and healthcare providers which in turn will boost the industry growth.

Based on cancer type, the basal cell carcinoma treatment market is divided into nodular, superficial spreading, sclerosing, and pigmented. The nodular segment accounted for significant market share of 66.5% in 2023.
 

• Nodular basal cell carcinoma (NBCC) typically presents as a noticeable nodule on the skin, making it easier to detect and diagnose early compared to other skin cancer subtypes that might be less visible or more aggressive.
   
• Also, early detection results in a higher number of diagnosed cases contribute to its prevalence. For instance, according to National Center for Biotechnology Information (NCBI), nodular basal cell carcinoma comprises about 60-80% of the skin cancers cases and occurs most often on the skin of the head. Thus, growing prevalence of NBCC among geriatric population will spur the segmental growth.

North America basal cell carcinoma treatment market is expected to grow at 8.3%, to reach USD 5.6 billion by the end of 2032.
 

• Basal cell carcinoma is the most common type of skin cancer in North America, accounting for a substantial portion of all diagnosed cases among BCC disease. For instance, according to American Cancer Society report, about 4 million basal and squamous cell skin cancers are diagnosed each year in the U.S.
   
• Thus, increasing incidence of such disease among aging population demographics, coupled with heightened awareness of skin cancer risks will supplement the country level market growth. Furthermore, the region boasts a well-established healthcare infrastructure, including numerous cancer hospitals and clinics equipped with advanced medical technologies.
   

The UK BCC treatment market is experiencing robust growth in European market.
 

• The incidence of basal cell carcinoma (BCC) in the UK has seen a notable increase over recent years. For instance, according to NHS Digital data released as part of the National Disease Registration Service (NDRS) Get Data Out (GDO) programme, there were 158,934 BCC cases in 2019, up from 128,406 in 2013. This surge implicates the growing demand for effective treatment solutions and presents significant opportunities within the UK BCC treatment market.  
   

The Asia Pacific BCC treatment market is witnessing substantial growth of 9.2% during the analysis period.
 

• The regional growth can be attributed to early detection of the disease which will influence the adoption trend for different treatment option. Also, the early detection not only increases the likelihood of successful treatment outcomes but also reduces the need for more invasive procedures, which can be expensive and more burdensome for patients especially in middle- and low-income economies. Thus, the integration of these advanced diagnostic tools into routine clinical practice is expected to contribute to the overall expansion of the BCC treatment market.
   

Basal Cell Carcinoma Treatment Market Share

The market is driven by continuous innovation and technological advancements. Leading companies offer a wide range of advanced cancer treatment including medications along with strategic initiatives to sustain the market competition. These companies are continually investing in research and development to introduce new products and enhance existing ones.
 

Basal Cell Carcinoma Treatment Companies

Prominent players operating in the basal cell carcinoma treatment industry include:

• Service providers
  • Cleveland Clinic
  • Dana-Farber Cancer Institute, Inc
  • Medical Tours
  • The Johns Hopkins University
  • The Ohio State University
• Medication manufacturers  
  • Almirall, S.A
  • Bausch Health Companies Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
     

Basal Cell Carcinoma Treatment Industry News:

• In October 2023, Sun Pharma's partner, Philogen, announced promising outcomes from late-stage clinical trials for its new drug, Nidlegy, designed for treating skin cancers. These findings signify a potential breakthrough in skin cancer treatment including basal cell carcinoma. This strategy is expected to enhance Sun Pharma's strategic partnership in advancing innovative therapies for oncological conditions.
   
• In February 2021, Sanofi received the approval from U.S. Food and Drug Administration (FD) for its Libtayo, as the initial immunotherapy for patients with advanced basal cell carcinoma. This approval extends to patients who have previously undergone treatment with a hedgehog pathway inhibitor (HHI) or for whom HHI treatment. This strategy helped the company to enhance its product offerings in the oncology sector.
   

The basal cell carcinoma treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Surgery
  • Type
    • Electrodessication and curettage
    • Standard surgical excision
    • Mohs surgery
    • Other surgery types
  • Treatment providers
    • Hospitals
    • Dermatology clinics
    • Cancer treatment centers
    • Other treatment providers
• Medication
  • Route of administration
    • Topical chemotherapy
    • Oral medications
  • Distribution channel
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
• Other treatment types

Market, By Cancer Type

• Nodular
• Superficial spreading
• Sclerosing
• Pigmented

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • The Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa